Consensus Sartorius Stedim Biotech

Equities

DIM

FR0013154002

Real-time Euronext Paris 12:39:48 2024-03-28 pm EDT 5-day change 1st Jan Change
264.3 EUR +0.76% Intraday chart for Sartorius Stedim Biotech -4.27% +10.35%

Evolution of the average Target Price on Sartorius Stedim Biotech

Price target over the last 5 years

History of analyst recommendation changes

c0e65db4f67a6f3886402eed5315ae3._gcoT7qE_GGXfOb7_TVQ3zb8WD1qzJK5cN2cTMwgN_s.uGROGePLni37DJC9q3Z9vFyfKkgQjeKJBJXEHr1jAbypbRsM1LS5Ff8zpw~f699f4a9f2bac3c4b67a8cabfcb22dd3
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating ZD
Berenberg: Sartorius Stedim Investors Await 'Several Strong Quarters' for Confidence Boost MT
SARTORIUS STEDIM BIOTECH : FY23: Updated mid-term outlook offers much-valued ‘certainty’ Alphavalue
SARTORIUS STEDIM : UBS raises its target price CF
Sartorius thwarted by 21-day line - despite HSBC recommendation DP
JPMORGAN : Sartorius outlook likely to be share price driver DP
SARTORIUS STEDIM BIOTECH : Opinion change, from Buy to Add Alphavalue
Sartorius continues to slide - low since April 2020 DP
Sartorius and subsidiary recover - JPMorgan praises biotech orders DP
SARTORIUS STEDIM BIOTECH : Disappointing preliminary Q3 23 puts mid-term outlook in question Alphavalue
Profit warning weighs heavily on Sartorius and subsidiary Stedim DP
SARTORIUS STEDIM BIOTECH : Jefferies reiterates its Buy rating ZD
Chinese headwinds could be more severe than expected Alphavalue
German Stocks Extend Losses Amid Rate Jitters Ahead of Monetary Policy Week MT
SARTORIUS STEDIM BIOTECH : Jefferies gives a Buy rating ZD
SARTORIUS STEDIM BIOTECH : Credit Suisse remains Neutral ZD
SARTORIUS STEDIM BIOTECH : Opinion change, from Buy to Add Alphavalue
SARTORIUS STEDIM BIOTECH : Q2 23 weakness overshadowed by positive management commentary Alphavalue
SARTORIUS STEDIM BIOTECH : UBS reiterates its Buy rating ZD
SARTORIUS STEDIM BIOTECH : Gets a Buy rating from JP Morgan ZD
SARTORIUS STEDIM BIOTECH : Target cut by -8.5% Alphavalue
SARTORIUS STEDIM BIOTECH : Weak start puts FY 23 guidance at risk Alphavalue
SARTORIUS STEDIM BIOTECH : Credit Suisse reiterates its Neutral rating ZD
SARTORIUS STEDIM BIOTECH : HSBC gives a Buy rating ZD
SARTORIUS STEDIM BIOTECH : Q4/FY22: soft FY 23 outlook overshadowed by FY 25 target upgrade Alphavalue
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
264.3 EUR
Average target price
261.2 EUR
Spread / Average Target
-1.16%
High Price Target
360 EUR
Spread / Highest target
+36.21%
Low Price Target
205 EUR
Spread / Lowest Target
-22.44%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sartorius Stedim Biotech

JEFFERIES James Vane-Tempest
alphavalue Virendra Chauhan
CREDIT SUISSE Dominic Lunn
JPMORGAN Richard Vosser
UBS Michael Leuchten
HSBC Rajesh Kumar
BERENBERG Odysseas Manesiotis
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings